Immutep Ltd

IMM

Company Profile

  • Business description

    Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.

  • Contact

    264 George Street
    Level 32, Australia Square
    SydneyNSW2000
    AUS

    T: +61 283157003

    E: [email protected]

    https://www.immutep.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2025

    Employees

    44

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,052.7080.40-0.99%
CAC 407,858.8317.53-0.22%
DAX 4022,390.84149.14-0.66%
Dow JONES (US)42,225.32235.360.56%
FTSE 1008,608.4826.32-0.30%
HKSE22,843.50359.03-1.55%
NASDAQ17,601.05151.160.87%
Nikkei 22534,688.871,037.00-2.90%
NZX 50 Index12,338.5718.380.15%
S&P 5005,670.9737.900.67%
S&P/ASX 2007,859.7074.80-0.94%
SSE Composite Index3,342.947.18-0.21%

Market Movers